Disc Medicine (IRON) EBITDA (2020 - 2026)
Disc Medicine (IRON) posted quarterly EBITDA of -$65.1 million for Q2 2026, down 5.97% year-over-year from -$69.2 million in Q2 2025, and up 6.4% quarter-over-quarter from -$69.5 million in Q1 2026.
Disc Medicine (IRON) EBITDA (2020 - 2026) Analysis & Trends
Disc Medicine (IRON) has reported EBITDA for 7 consecutive years, with -$65.1 million the latest figure, recorded in Q2 2026.
- In Q2 2026, EBITDA fell 5.97% year-over-year to -$65.1 million; the TTM figure through Jun 2026 stood at -$269.3 million (down 59.55% YoY), while the FY2025 annual figure was -$236.0 million, down 81.95% from the prior year.
- EBITDA improved to -$65.1 million in Q2 2026 per IRON's latest filing, from -$69.5 million in the prior quarter.
- Across five years, EBITDA topped out at -$10.0 million in Q1 2022 and bottomed at -$69.5 million in Q1 2026.
- Historically, EBITDA has averaged -$35.5 million across 5 years, with a median of -$31.2 million in 2024.
- On a YoY basis, EBITDA climbed as much as 43.2% in 2022 and fell as far as 173.9% in 2022.
- Disc Medicine's EBITDA stood at -$15.0 million in 2022, then sank by 97.82% to -$29.7 million in 2023, then fell by 16.28% to -$34.6 million in 2024, then slumped by 93.84% to -$67.0 million in 2025, then gained by 2.83% to -$65.1 million in 2026.
- Business Quant data shows IRON's EBITDA at -$65.1 million in Q2 2026, -$69.5 million in Q1 2026, and -$67.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Disc Medicine | 3.02 Bn | 3.02 Bn | - | -65.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -65.08 Mn |
| Mar 31, 2026 | -69.52 Mn |
| Dec 31, 2025 | -66.97 Mn |
| Sep 30, 2025 | -67.70 Mn |
| Jun 30, 2025 | -61.41 Mn |
| Mar 31, 2025 | -39.95 Mn |
| Dec 31, 2024 | -34.55 Mn |
| Sep 30, 2024 | -32.86 Mn |
| Jun 30, 2024 | -30.85 Mn |
| Mar 31, 2024 | -31.46 Mn |
| Dec 31, 2023 | -29.71 Mn |
| Sep 30, 2023 | -18.96 Mn |
| Jun 30, 2023 | -17.33 Mn |
| Mar 31, 2023 | -25.13 Mn |
| Dec 31, 2022 | -15.02 Mn |
| Sep 30, 2022 | -10.48 Mn |
| Jun 30, 2022 | -12.02 Mn |
| Mar 31, 2022 | -9.96 Mn |
| Dec 31, 2021 | 20.33 Mn |
| Sep 30, 2021 | -18.45 Mn |